Welcome to the Trawick Group!
The Trawick Group focuses on the design and evaluation of new compounds as therapeutic agents through enzyme kinetics and assays, mammalian cell culture, molecular modeling and protein purification. Specific applications include the discovery and development of vascular disrupting agents for the treatment of solid tumors and ophthalmologic disorders, and development of new compounds to treat metastatic cancer and Chagas’ disease.
The mechanism of enzyme action is a primary research target of the Trawick Group with special emphasis on cysteine proteases including cruzain and several cathepsins, transglutaminase, and gamma-glutamylamine cyclotransferase. For these studies we use the biochemical evaluation of enzyme substrates and inhibitors, molecular modeling, and kinetics. We are very involved in the design and application of enzyme inhibitors in the potential treatment of parasitic diseases, and as anticancer agents including the evaluation of compounds as inhibitors of cell invasion as potential inhibitors of tumor metastasis.
List of Research Projects
- Molecular Modeling of Enzyme Active Sites and Inhibitor Docking
- Inhibitors of Cathepsin L as Inhibitors of Tumor Metastasis
- New Drug Development for the Treatment of Chagas’ and Other Parasitic Diseases
- Evaluation of New Anti-Tumor Inhibitors of Tubulin Assembly (Polymerization)
- Discovery of Improved Vascular Disrupting Agents for Cancer Chemotherapy and Their Mechanism of Action
- Targeting Tumor Hypoxia with Bioreductively Activated Compounds
- Design, Synthesis and Evaluation of Substrates and Inhibitors of gamma-Glutamylamine Cyclotransferase
- Metabolism of Crosslinked Proteins
- Purification of Tubulin and Enzymes Listed Above